ProMIS(TM) Neurosciences Appoints William C. Mobley to Scientific Advisory Board
(Thomson Reuters ONE) -
TORONTO and CAMBRIDGE, Mass., June 06, 2017 (GLOBE NEWSWIRE) -- ProMIS
Neurosciences, Inc. (TSX:PMN), a biotechnology company focused on the discovery
and development of precision treatments for neurodegenerative diseases, today
announced the appointment of William C. Mobley, M.D., Ph.D., to the Company's
scientific advisory board (SAB). Dr. Mobley is Associate Dean for Neurosciences
Initiatives, Distinguished Professor of Neurosciences, Florence Riford Chair for
Alzheimer Disease at the University of California, San Diego (UCSD), and the
university's Executive Director of the Down Syndrome Center for Research and
Treatment.
"We are delighted that Bill has joined our renowned Scientific Advisory Board,"
stated Dr. Neil Cashman, ProMIS Chief Scientific Officer and co-chair of the
SAB. "As one of the most prominent academic neurologists in the U.S., Bill
brings an outstanding record of achievement in the field of neurodegenerative
diseases. We look forward to his insightful contributions to our programs
targeting toxic forms of Amyloid beta in Alzheimer's disease and Down syndrome."
Commenting on the appointment, Dr. Mobley stated: "The important role played by
toxic, prion-like forms of Amyloid beta in the development and progression of
Alzheimer's disease is now well established. I look forward to contributing my
expertise in this field to the ProMIS Scientific Advisory Board, as the Company
develops antibody therapeutics selectively targeting these toxic proteins for
the treatment of Alzheimer's disease and potentially address the cognitive
decline in Down syndrome."
William C. Mobley, M.D., Ph.D., holds numerous leadership roles across
neuroscience, Alzheimer's disease, and Down syndrome at the University of
California, San Diego (UCSD). He is recognized nationally and internationally
for his research on degenerative disease of the central nervous system.
Previously, Dr. Mobley served as the John E. Cahill Family Professor in the
Department of Neurology and Neurological Sciences at Stanford University, where
he was also the founding director of the university's Neuroscience Institute.
Dr. Mobley's research focuses on the neurobiology of neuronal dysfunction in
developmental and age-related disorders of the nervous system. He has conducted
pioneering work on the neurobiology of Alzheimer's disease and his emphasis on
the neurobiology of Down syndrome has brought new insights into the condition,
including possible treatments.
Dr. Mobley has received many awards and distinctions. He is a member of the
Institute of Medicine, National Academy of Sciences. He collaborated with the
Dalai Lama to create the Center for Compassion and Altruism Research and
Education at Stanford University. He also serves as the expert advisor to the
Congressional Down Syndrome Caucus. He was recipient of the Christian Pueschel
Memorial Award in 2007, the International Sisley-Jérôme Lejeune Prize in 2011
and the Dr. William Cohen Researcher of Distinction Award from the LuMind
Foundation in 2015.
About the ProMIS Scientific Advisory Board
The ProMIS SAB brings together a multidisciplinary group of specialists in
Alzheimer's and neurodegenerative disease along with experts in neurotoxic,
prion-like misfolded proteins. In addition to Dr. Mobley, the current members of
the Company's SAB are:
* Todd E. Golde, M.D., Ph.D., is Director of the Center for Translational
Research in Neurodegenerative Disease at the University of Florida where he
directs a robust program of scientific discovery aimed at translating basic
discoveries in neurodegenerative disease into diagnostics and treatments for
patients. Dr. Golde is co-chair of the SAB;
* Neil R. Cashman, M.D., is Chief Science Officer at ProMIS Neurosciences and
Professor of Medicine at the University of British Columbia, where he holds
the Canada Research Chair in Neurodegeneration and Protein Misfolding
Diseases, and serves as the Director of the UBC ALS Centre. Dr. Cashman is
recognized as a pioneer in the field of prion-like misfolded proteins and
their role in development of neurodegenerative diseases, in particular ALS
and AD. Neil Cashman is co-chair of the SAB;
* Lary C. Walker, Ph.D., is Associate Professor of Neurology and Research
Professor at Emory University Yerkes National Primate Research Center. Lary
Walker's research has been directed toward understanding the mechanisms by
which the Alzheimer-associated proteins Amyloid beta and tau form pathogenic
assemblies in vivo and how these agents spread in the brain.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO),
headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts.
The mission of ProMIS is to discover and develop precision medicine therapeutics
for effective treatment of neurodegenerative diseases, in particular Alzheimer's
disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of
two, complementary techniques. The Company applies its thermodynamic,
computational discovery platform-ProMIS((TM)) and Collective Coordinates - to
predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular
surface of misfolded proteins. Using this unique "precision medicine" approach,
ProMIS Neurosciences is developing novel antibody therapeutics and specific
companion diagnostics for Alzheimer's disease and ALS. The company has also
developed two proprietary technologies to specifically identify very low levels
of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences
owns a portfolio of therapeutic and diagnostic patents relating to misfolded
SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic
against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release. This information release may contain certain forward-
looking information. Such information involves known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by statements herein,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on the
Company's current beliefs as well as assumptions made by and information
currently available to it as well as other factors. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties, including the
risks and uncertainties identified by the Company in its public securities
filings, actual events may differ materially from current expectations. The
Company disclaims any intention or obligation to update or revise any forward-
looking statements, whether as a result of new information, future events or
otherwise.
For further information please consult the Company's website at:
www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
For media inquiries, please contact:
Scott Santiamo
RussoPartners/LLC
Scott.Santiamo(at)russopartnersllc.com
Tel. 718 344-5843
David Schull
RussoPartners/LLC
David.Schull(at)russopartnersllc.com
Tel. 858 717-2310
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein(at)promisneurosciences.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 06.06.2017 - 18:43 Uhr
Sprache: Deutsch
News-ID 546590
Anzahl Zeichen: 8742
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 503 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProMIS(TM) Neurosciences Appoints William C. Mobley to Scientific Advisory Board"
steht unter der journalistisch-redaktionellen Verantwortung von
ProMIS Neurosciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
